Deutsche Märkte geschlossen

Johnson & Johnson (JNJ)

NYSE - Nasdaq Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
176,98+3,04 (+1,75%)
Ab 04:00PM EDT. Markt geöffnet.
Melden Sie sich an, um eine Nachricht zu posten.
  • P
    Peter
    $ATNF conversation
    Buyout is fully in place no new insider purchases, and it makes sense too close to a deal.
    $ATNF $XBI buyer could be $JNJ $ABBV
  • n
    nicholas
    $ATNF conversation
    Getting 180 Life Sciences multi-billion dollar acquisition deal across the line requires a massive amount of effort. It starts with initial discussions then evolves into full-fledged negotiations, sometimes with multiple suitors at once. Once the outline of a deal is reached, the potential acquirer spends several weeks doing due diligence and peppering company insiders with detailed questions about the business. Dealing with all this plus the prospect of a massive payday down the line is super distracting there has been not a lot of updates recently from 180 Life Sciences even though major milestone was achieved, namely Dupuytren's disease P2B data fully published via Lancet Rheumatology. $ATNF $ABBV $JNJ (Small biotechs usually become themselves target of acquisition due to cash constraints and with viable intellectual portfolio like 180 Life Sciences a full sale of this company is to be warranted and it may be in the best interest of all stakeholders and shareholders alike. Management needs to fight like crazy to maximize the premium paid to shareholders and all accretive acquisitions must be paid fully in cash)
  • M
    Mark
    $ATNF conversation
    Buyout of $ATNF for couple billions cash from $JNJ $GSK $ABBV . I strongly support buyout to monetize the recent results of Dupuytren's disease phase 2b results.
  • P
    Peter
    $ATNF conversation
    The fundamental thesis of anti-TNF pipeline a very 'high probability' pipeline is proven to be correct and company can easily partner to commercialize Dupuytren or even sell itself to $ABBV $JNJ
  • P
    Peter
    $ATNF conversation
    Baffling. Added another round. All in all Maxim comes out and says nothing new. After positive DD P2D the next phase will be partnership or management could sell entire company to $ABBV $JNJ Buy/Hold Maxim literally said hold what bunch of quacks
  • Э
    Эльзар
    $UPST conversation
    investors buy $pg or $jnj - p/e 35 , and sell $nflx p/e 20 and $fb p/e15 , and sell $upstart f p/e 20 and grow 30% y , very strange logic , oil stock overprices p/e tech stocks, incresable
  • T
    Tad
    $ARWR conversation
    from bikerieder on twitter:

    when pressed by madhu Kumar on talks with the fda concerning streamlining the aat trial, here was ca's response: Ca on aat study: “so Javier is probably dying to answer that question…but I can’t let him…here’s the deal. We were so excited about those data for a lot of reasons. I believe that it suggested this drug is doing what we wanted to do. In fact, doing a bit faster than we expected. And so we are going with those data and probably some additional data to the fda to talk about changing endpoints and changing size and maybe changing the duration of the study. Until we have those discussions, it’s probably not appropriate for us to speculate on the specifics of what those changes could be. I don’t want to get out in front of this conversation. We’ve had a very good collaborative relationship with the fda as it relates to this program, we expect this to continue to be collaborative, and I just don’t want to jeopardize that. I want to have the discussion, an open discussion with them and then come back to you and tell you what we have decided together.”

    then Mariano: "BIG STEP, $ARWR ARO-AAT showing polymer reduction both in liver cells and in serum. $TAK must have been convinced Arrowhead Pharma’s drug for A1AD will be a winner! Equates to same scenario as with $JNJ J&J purchase of ARO-HBV asset, too."

    color on the ongoing dialogue could come sooner than we think....just another short-term catalyst for arwr longs.
  • A
    ApexGambit
    Vaxart, Inc.
    $VXRT PR team did the right thing by not releasing P1 results this week- as too much noise from $NVAX and $JNJ releasing their results. Next week the spotlight is for Vaxart alone 😁
  • C
    Chris
    $ARWR conversation
    Taken from Mark C on Twitter:So lets recap, $ARWR & its partners $AMGN / $JNJ will be presenting data on 5 of ARWR #RNAi drugs in the coming days at #AASLDglobal & #AHA2020 . This is unprecedented, especially when you consider the marketsize/blockbuster status of at least 4 of these drugs. FIVE! #HBV #AAT
  • J
    Jad
    $NVAX conversation
    *FDA EXPECTED TO ANNOUNCE NEW WARNING ON $JNJ COVID VACCINE: WAPO

    'the shot has been linked to a serious but rare side effect — Guillain-Barré syndrome, in which the immune system attacks the nerves, according to four individuals familiar with the situation.'
  • T
    Tom
    $NVAX conversation
    Found this on Twitter.

    #EMA approval

    #AstraZeneca filed on 01/12 2021
    approval on 01/29 2021
    17 days

    #Pfizer filed on 11/30 2020
    approval on 12/21 2020
    21 days

    #Moderna filed 12/01 2020
    approval 01/06/2021
    37 days

    #JNJ filed 02/15/2021
    approval 03/11/2021
    24days

    $NVAX filed on 11/17 2021
    it has been 20 days
  • R
    Retired7211
    $ARWR conversation
    From our friends at GS per Twitter:
    $VIR GS: compares favorably to $JNJ $ARWR though we note key diffs btwn studies including duration, no. of doses (3x JNJ vs 2x VIR). Safety appears favorable for VIR, w/ headaches only reported txAE compared to single events of elevated of creatinine and ALT observed in JNJ.

    Perhaps impetus for JNJ to keep the petal to the metal!
  • N
    Neil
    $NVAX conversation
    2/7/21 CV19 Latest Efficacy Variants%:
    [Overall%,🇨🇳prim%,🇬🇧var%,🇿🇦var%,🇧🇷var%]

    1. $NVAX [$19B]: [89%,96%,86%,60%,NA]
    2. $AZN [$130B]: [82%,NA,NA,no bueno,NA]
    3. $MRNA [$70B]: [NA,95%,NA,NA,NA]
    4. $BNTX [$28B]: [NA,95%,NA,NA,NA]
    5. $JNJ [$432B]: [66%,72%,NA,57%,NA]
    6. $CVAC [$22B]: [NA,NA,NA,NA,NA]
    7. $INO [$2.2B]: [NA,NA,NA,NA,NA]
    8. $VXRT [$0.8B]: [NA,NA,NA,NA,NA]

    ---------------
    AZN & JNJ 1st solutions are in trouble. They need quick turnaround with next versions to handle primary & 3+ variants.
    ---------------
    Since multiple variants are identified, the race is wide open again for the small horses to catch up.
    ---------------
    CV19 terminologies:
    1. Sars-CoV2 -- 🇨🇳primary
    2. B117-- 🇬🇧variant
    3. B1351 -- 🇿🇦variant
    4. P1 -- 🇧🇷variant
    ---------------
    Notes:
    +These are rough numbers provided by vaccine makers. Check their PRs.
    +JNJ vaccine is single shot 💉.
    +VXRT vaccine comes in pill 💊 form.
    +INO vaccine is DNA platform.
    +NVAX 🇿🇦variant% is for HIV-.
  • C
    Chris
    $ARWR conversation
    The Ravid on Twitter this morning :$ARWR has vast pipeline including several later stage assets, partnership with Janssen $JNJ for multiple assets, license with Amgen $AMGN; if they do 1 drug w/$1B sales @ 4x multiple (on a sale), you cover the current valuation, get the rest of platform and pipeline free.
  • N
    Neil
    $NVAX conversation
    2/5/21 CV19 Latest Efficacy Variants%:
    [Overall%,🇨🇳prim%,🇬🇧var%,🇿🇦var%,🇧🇷var%]

    1. $MRNA [$68B]: [NA,95%,NA,NA,NA]
    2. $BNTX[$28B]: [NA,95%,NA,NA,NA]
    3. $JNJ [$426B]: [66%,72%,NA,57%,NA]
    4. $NVAX [$19B]: [89%,96%,86%,60%,NA]
    5. $AZN [$132B]: [82%,NA,NA,NA,NA]
    6. $CVAC [$19B]: [NA,NA,NA,NA,NA]
    7. $INO [$2.5B]: [NA,NA,NA,NA,NA]
    8. $VXRT [$0.9B]: [NA,NA,NA,NA,NA]

    ---------------
    Since multiple variants are identified, the race is wide open again for the small horses to catch up.

    Will see if mRNA technology can react quickly to mutating variants as advertised

    ---------------
    CV19 terminologies:
    1. Sars-CoV2 -- 🇨🇳primary
    2. B117-- 🇬🇧variant
    3. B1351 -- 🇿🇦variant
    4. P1 -- 🇧🇷variant
    ---------------

    Notes:
    +These are rough numbers provided by vaccine makers. Check their PRs.
    +JNJ vaccine is single shot 💉.
    +VXRT vaccine comes in pill 💊 form.
    +INO vaccine is DNA platform.
    +NVAX 🇿🇦variant% is for HIV-.
  • C
    Chang
    $MRNA conversation
    BREAKING—CDC study confirms the NIH-Moderna COVID19 vaccine is more effective against DeltaVariant hospitalizations than $PFE/$BNTX or $JNJ. Vaccine efficacy for Delta—Moderna 95%, Pfizer 80%, J&J 60%. VE also higher in age <74.
  • b
    best_ivideo
    $BNTX conversation
    It does not matter whether or not you own $PFE, $BNTX, $MRNA, $VXRT, $JNJ. I do not work in the healthcare industry. Waiving IP protection for covid vaccines by the current US government administration is appalling. Instead of encouraging and protecting innovations, US government caters to the pressure from other countries by giving away patents registered by private companies.

    As more COVID variants and potential new future pandemics arise, who will invest and take risks to innovate without IP protection?

    Production of COVID vaccines is a complex scientific process and requires know-how, raw materials, strict quality controls. Waiving IP protections will not lead to increased production of vaccine doses. Without IP protection, on the contrary, it will make limited availability of raw materials scarcer to source; quality of vaccine doses will drop; counterfeits will rise. This can disrupt the global supply chain in very needed vaccines required for booster shots, and further complicate and create a global health crisis.

    Please write to your US senators and house representatives from your State, and tell them the US government should take the leadership by being right instead of being popular.
  • T
    TropicalPlants21
    $OCGN conversation
    Today is for $JNJ and let them have it. We longholder, $OCGN can wait and we will have our turn !
  • M
    Miguel
    $MRNA conversation
    $MRNA, $BNTX, $NVAX, $JNJ, $PFE, investors need to start a class action lawsuit. Not just against the USG & WHO, but call out names, U.S. Trade Rep Katherine Tai Tedros, WHO D.G. Adhanom Ghebreyesus, & Pres JB.
    I've invested not just money, but 20 months (Pre-covid long MRNA). Never sold, just accumulated shares over time. In the early days, I knew the risk, maybe the mRNA biotech wouldn't work. NOW the tech works, but the risk comes from the WH & WHO...
    Good luck ALL longs from each company...
  • D
    Dan
    $AMD conversation
    Inverse relationship between AMD strength and $MU losses not surprising. The 1 year chart is almost a perfect inversion model. A mirror image only AMD is likely over 100% to MU's 85% decline. $INTC falls in a similar pattern though not as severe. Overall, AMD is holding up well with the China matter and I expect it will continue.

    $SNAP also holding up well in the tech sector for 2019. Evan Speigel doing what it takes to mold the executive team around his vision. Elon allowing buyout talk to help the stock isn't a bad strategy. Consider $TSLA a hold at this time.

    Washington will impact pharma greatly if it chooses to - I am betting for relative status quo and remain interested in the sector. For now, $BIIB and $JNJ are my only holdings. Both long term plays on strong balance sheets.

    My friends who played energy yesterday did well. I was still sidelined and will stay here until environment stabilizes.

    Your feedback has been constructive on most matters. Thank you.

    I wish all a great Memorial Day weekend.